iCarbonX

iCarbonX is focused on creating a comprehensive ecosystem of digital health by integrating consumers' life data with artificial intelligence and biotechnology. The company, founded by a team with extensive experience in omics technology and data analysis from BGI Tech, aims to establish a leading data collection platform for health information in China. By gathering a wide range of data—including genomic, phenotypic, behavioral, social, and environmental factors—iCarbonX provides personalized health analyses and predictions. Its platform is designed to empower individuals to understand their genetic profiles and make informed decisions about their health and well-being, leveraging advanced data mining and machine learning techniques.

Hao Li

Co-Founder, Chief Information Officer and Board Member

Jun Wang Ph.D

Co-Founder, Board Member and CEO

Chun Wu

Co-Founder and COO

Cindy Yang

Chief Investment Officer and Partner

8 past transactions

Reach Media

Series B in 2018
Shanghai Reach Media Co., Ltd. is an advertising services provider founded in 2014 and headquartered in Shanghai, China. The company specializes in creating advertising opportunities within medium to high-end communities. Its services include advertising bulletin boards that focus on cultural community activities and service-oriented information channels. This approach allows businesses to effectively promote their products and services while enabling communities to share important news and updates with residents. Through these targeted advertising solutions, Reach Media aims to connect companies with a broader consumer base.

SomaLogic

Private Equity Round in 2018
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

HealthLoop

Series B in 2017
HealthLoop, Inc. operates a software-as-a-service platform that supports medical practices in monitoring patient recovery through ongoing communication and symptom tracking. Founded in 2009 and based in Moffett Field, California, the platform enables healthcare providers to identify patients at risk of decline during the follow-up period. By collecting patient feedback and comparing their recovery status against expected progress, HealthLoop facilitates timely alerts to physicians regarding potential treatment failures, complications, or hospital readmissions. The company primarily serves medical offices across the United States, aiming to enhance patient engagement and improve overall care coordination.

PatientsLikeMe

Venture Round in 2017
PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.

AOBiome

Series C in 2017
AOBiome, LLC, a biotechnology company, develops topical biologics for the treatment of inflammatory skin conditions. It focuses on transforming human health through products that restore ammonia-oxidizing bacteria. The company develops therapeutics to improve skin health, hypertension, and other systemic conditions. It also owns the Mother Dirt branded line of consumer products that restore and maintain the balance of the skin biome. AOBiome, LLC was formerly known as NitroCell BioSciences LLC and changed its name to AOBiome, LLC in May 2013. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Imagu Vision Technologies

Acquisition in 2016
Imagu Vision Technologies has developed image understanding technologies applied to various industries, including healthcare, medical imaging, semiconductors, homeland security, and e-commerce. Imagu is dedicated to developing software for image understanding with the mission of enabling machines to understand their environment. Imagu Vision Technologies develop software for object recognition in digital images and video. Imagu Vision Technologies pioneering technology enables us to customize our software to numerous object types, environments and image sources, in accordance with the requirements of our customers. Imagu Vision Technologies provide high performance solutions at extremely short time.

NongFaDai

Series A in 2016
Developer of a P2P lending platform designed to offer financing services to agricultural producers. The company's platform extends loans to farmers through user investment, enabling borrowers to expand production and investors to allocate their wealth efficiently.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.